The search for a vaccine to prevent HIV has been a 30-year quest. For over a decade, we have focused on delivering breakthrough science to stop the transmission of infection—a critical goal if we are to end this epidemic.
We remain dedicated to fulfill our mission of delivering transformational innovations to meet the diverse needs of the HIV community and are excited to be bringing forward an evolved therapy with darunavir as its backbone.
Non-adherence to treatment remains a challenge for many people living with HIV and one of the main drivers of resistance to HIV medicines. Our hope is to make HIV treatment manageable for all by developing innovative solutions like long-acting regimens.
Scientists discover the virus that causes AIDS.
The first International AIDS Conference (IAC) takes place.
The World Health Organization declared December 1st to be World AIDS Day.
The U.S. Centers for Disease Control and Prevention (CDC) issues the first national treatment guidelines for the use of ARV therapy in adults and adolescents.
Approximately 3.5 million new infections occur in Sub-Saharan Africa.
In 2006, Johnson and Johnson launched the Global Access and Partnerships Program, a global HIV drug access program.
Janssen’s Novel Protease Inhibitor Is Approved in the U.S.
Janssen’s non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved in the E.U. and U.S.
WHO estimates 5.2 million people receiving treatment for HIV.
Janssen and IAVI enter into an agreement to develop a preventive HIV vaccine based on Janssen's AdVac® adenovirus vector technology.
Janssen partners with The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and the Partnership for Supply Chain Management System (PFSCMS) to implement New Horizons Advancing Pediatric HIV Care Collaborative.
Janssen announces first-of-its kind drug donation program for HIV treatment-experienced children.
UNAIDS sets 90-90-90 goals in a bid to end the AIDS epidemic.
Agreement in 112 countries to manufacture generic versions of Janssen's NNRTI.
Janssen announces expanded collaboration with International Partnership for Microbicides for Development and Commercialization of NNRTI for prevention of sexual transmission of HIV.
Study published in Science highlights potential of investigational preventive vaccine regimen.
International Phase I/IIa clinical trial commences to evaluate safety and immunogenicity of Janssen’s HIV preventive vaccine regimen in healthy, HIV-uninfected volunteers.
Major new global commitments to end HIV infection in adolescent girls and women announced.
License granted for Janssen’s protease inhibitor to be developed and commercialized in a number of developing countries to support HIV prevention in women.
The historic challenge of finding an HIV vaccine requires global collaboration.